Get the latest news on Franklin Genomic Advancements ETF stock with updates on market trends, financials, and analysis from Benzinga. Stay informed on HELX performance

Latest Franklin Genomic Advancements ETF  News | BATS:HELX | Benzinga

Healthcare

Other

Basic Materials

Technology

Industrials

Real Estate

The Fund invests in equity securities inside and outside of the United States, including developing or emerging markets.

Medpace Holdings Inc

Nvaesrtex Pharmaceuticals Inc

Regeneron Pharmaceuticals, Inc.

Danaher Corp.

Thermo Fisher Scientific Inc

Krystal Biotech Inc

Eli Lilly & Co.

Samsung Biologics Co Ltd

Natera Inc

Astrazeneca Plc, ADR

Franklin Genomic Advancements ETF

Genetic,Research,And,Biotech,Science,Concept.,Human,Biology,And,Pharmaceutical

Analyst Color

Earnings

Equities

Large Cap

News

Guidance

Reiteration

Analyst Ratings

Movers

Trading Ideas

AMID

HELX

MEDP

Medpace Holdings reports Q3 results with revenue of $533.3M, below consensus. Backlog and EBITDA increased. Medspace lowered its FY24 revenue forecast.

Why Is Medpace Stock Diving On Tuesday?

Medpace Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MEDP#NASDAQ">MEDP</a>) shares are trading lower on Tuesday after reporting its third-quarter financial results yesterday.



Revenue rose 8.3% year-over-year to $533.3 million, missing <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/b41439111/medpace-holdings-inc-reports-third-quarter-2024-results" rel="noreferrer noopener">the consensus of $540.99 million</a>.



On a constant currency basis, revenue increased by 8.1% in the quarter. As of September 30, backlog rose by 8.8% to $2.927 billion.



Net new business awards totaled $533.7 million for the third quarter of 2024, resulting in a net book-to-bill ratio of 1.00x, compared to&nbsp;$611.5 million&nbsp;in the prior year.



EBITDA rose 31.7% to $118.8 million, with a margin of 22.3% versus 18.3% a year ago.



As of September-end, the company held $656.9 million in cash and cash equivalents and generated $149.1 million in operating cash flow in the third quarter.



The company didn&#8217;t repurchase any shares during the quarter, leaving $308.8 million available under the authorized share repurchase program.



Outlook: Medspace lowered its FY24 revenue forecast from $2.125 billion&nbsp;&#8211;&nbsp;$2.175 billion to $2.090 billion &#8211; $2.130 billion versus the<a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener"> consensus of $2.138 billion</a>.



The company expects EPS of $11.71 &#8211; $12.09 (prior view $11.24&nbsp;&#8211; $11.93) compared to the estimate of $11.56.



William Blair analyst Max Smock stated that they suspect that elevated cancellations may have contributed to the weak net bookings, which is preferable to a significant drop in gross bookings due to a lower win rate.



The analyst says that given the rebound in biotech funding observed this year, particularly in September, investors may be able to buy the dip if gross bookings remain stable and management provides clarity on cancellations.



However, the analyst adds that without further insight into the third-quarter bookings miss, it&#8217;s uncertain whether this pullback presents a compelling buying opportunity or indicates ongoing challenges. The analyst <a target="_blank" href="https://www.benzinga.com/quote/MEDP/analyst-ratings" rel="noreferrer noopener">reiterated the Outperform rating.</a>



Investors can gain exposure to the stock via Franklin Genomic Advancements ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/HELX#BATS">HELX</a>) and Argent Mid Cap ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMID#NASDAQ">AMID</a>).



Price Action: MEDP shares are down 8.76% at $322.00 at the last check Tuesday.



Photo via Shutterstock



Read Next:



<ul>
<li><a href="https://www.benzinga.com//node/41445327" target="_blank" rel="noreferrer noopener">Qualcomm&#8217;s New Chipset Brings Multi-Modal Generative AI To Android Phones, Boosting Competition With iPhone 16</a></li>
</ul>

Comments

Franklin Genomic Advancements ETF Stock News

News

Latest Franklin Genomic Advancements ETF News | BATS:HELX | Benzinga

Tuesday, October 22, 2024

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga